Exploitation of human mesenchymal stromal cell derived matrix towards the structural and functional restoration of the ocular surface

Yan, Dongpeng; Yan, Chenxi; Yu, Fei; Zhang, Siyi; Chen, Liangbo; Wu, Nianxuan; Shao, Chen; Yao, Qinke; Sun, Hao; Fu, Yao

doi:10.1039/d0bm00787k

Cited by 13 publications

(10 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3] Cell-derived dECM is exceptionally suitable for both in vitro research and therapeutic applications. Its value for skeletal tissue engineering, [21][22][23] cardiovascular tissue engineering, [24,25] wound healing, [26,27] and ocular surface reconstruction [28,29] has been extensively explored.…”

Section: Cell-derived Decmmentioning

confidence: 99%

Emerging Strategies for Optimizing Cell‐Derived Decellularized Extracellular Matrix Scaffolds in Tissue Engineering

Chen,

Zhang,

2024

Adv Eng Mater

Self Cite

View full text Add to dashboard Cite

As an ideal biological scaffold, cell‐derived decellularized extracellular matrix (dECM) is attracting increasing attention and has been prepared and studied for tissue engineering. However, a few barriers prevent its extensive clinical usage, indicating that it requires further optimization. This review starts with a brief introduction to the benefits and limitations of dECM as a biomaterial. Then, it provides a novel perspective summarizing and describing methods for dECM optimization, delineating strategies to optimize regular cell‐derived dECM sheet preparation and additional biochemical or mechanophysical procedures to further modify the scaffold. These innovative approaches equip engineered biomaterials based on cell‐derived dECMs with key properties and functionalities, thus providing a great opportunity for their broader future therapeutic applications. Finally, several ideas and directions for future development are also prospected.This article is protected by copyright. All rights reserved.

show abstract

Section: Cell-derived Decmmentioning

confidence: 99%

Emerging Strategies for Optimizing Cell‐Derived Decellularized Extracellular Matrix Scaffolds in Tissue Engineering

Chen,

Zhang,

2024

Adv Eng Mater

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies revealed that mesenchymal stromal (or stem) cells (MSCs) could survive and differentiate into adult human keratocytes in animal models without eliciting an inflammatory response. In addition, they produced new collagen in the host stroma and were able to remodel scars and improve transparency in animal models for corneal dystrophies [14,15]. Cell-based therapies can be broadly divided into using stem cells to stimulate regeneration with and without scaffolds.…”

Section: Cell-based Therapiesmentioning

confidence: 99%

Advances in Biomaterials for Corneal Regeneration

Malhotra¹,

Griffith²

2023

Eye Diseases - Recent Advances, New Perspectives and Therapeutic Options

View full text Add to dashboard Cite

The human cornea acts as a protective covering for the eye and plays an important role in light transmission into the eye for vision. Corneal defects due to trauma, infection, or disease can have detrimental effects on the vision, and severe cases lead to vision loss. Twenty-three million people are estimated to be affected by corneal blindness worldwide. Treatment involves corneal transplantation surgery, but there is a severe shortage of donor corneas worldwide. Furthermore, patients with severe pathologies risk rejecting conventional corneal transplantation, thus leaving them untreated. Therefore, there is an urgent need to develop new therapies to replace traditional corneal transplant surgery. This review focuses on recent potential biomaterials development for corneal regeneration and repair. It includes cell-based therapies, cell-free regeneration-inducing biomaterials, and injectable or in-situ gelation-based biomaterials for patients with a high risk of graft failure. It also consists of the emerging role of exosomes and extracellular vesicles in corneal infections and regeneration.

show abstract

“…As of February 2022, there were three clinical trials on the ClinicalTrials.gov website ( Table 2 ). In previous studies, MSC treatment of ocular surface diseases mainly included tissue transplantation 65 , periorbital injection 57 , 63 , topical drops 66 , and intravenous injection 67 ( Fig. 2 ).…”

Section: Application Of Mscs In Dry Eye Treatmentmentioning

confidence: 99%

Mesenchymal Stromal Cell–Based Therapy for Dry Eye: Current Status and Future Perspectives

2022

View full text Add to dashboard Cite

Dry eye is one of the most common chronic diseases in ophthalmology. It affects quality of life and has become a public health problem that cannot be ignored. The current treatment methods mainly include artificial tear replacement therapy, anti-inflammatory therapy, and local immunosuppressive therapy. These treatments are mainly limited to improvement of ocular surface discomfort and other symptoms. In recent years, regenerative medicine has developed rapidly, and ophthalmologists are working on new methods to treat dry eye. Mesenchymal stromal cells (MSCs) have anti-inflammatory, tissue repair, and immune regulatory effects, and have become a promising tool for the treatment of dry eye. These effects can also be produced by MSC-derived exosomes (MSC-Exos). As a cell-free therapy, MSC-Exos are hypoimmunogenic, serve more stable entities, and compared with MSCs, reduce the safety risks associated with the injection of live cells. This article reviews current knowledge about MSCs and MSC-Exos, and highlights the latest progress and future prospects of MSC-based therapy in dry eye treatment.

show abstract

Exploitation of human mesenchymal stromal cell derived matrix towards the structural and functional restoration of the ocular surface

Abstract: Decellularized matrix of ADMSCs is a promising conjunctival substitute with superb wound repairing property by promoting proliferation of conjunctival epithelial cells and restoring goblet cells without causing cosmetic differences.

Cited by 13 publications

References 45 publications

Emerging Strategies for Optimizing Cell‐Derived Decellularized Extracellular Matrix Scaffolds in Tissue Engineering

Emerging Strategies for Optimizing Cell‐Derived Decellularized Extracellular Matrix Scaffolds in Tissue Engineering

Advances in Biomaterials for Corneal Regeneration

Mesenchymal Stromal Cell–Based Therapy for Dry Eye: Current Status and Future Perspectives

Contact Info

Product

Resources

About